FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2521009540> ?p ?o ?g. }

• W2521009540 endingPage "180" @default.
• W2521009540 startingPage "171" @default.
• W2521009540 abstract "Objectives The aim of the study was to determine the time to, and risk factors for, triple-class virological failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV infection and older adolescents and adults with heterosexually acquired HIV infection. Methods We analysed individual patient data from cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection and 15–29 years for those with heterosexual infection, with ART containing at least two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the most recent viral load (VL) measurement. Virological failure of a drug was defined as VL > 500 HIV-1 RNA copies/mL despite ≥ 4 months of use. TCVF was defined as cumulative failure of two NRTIs, an NNRTI and a bPI. Results The median number of weeks between diagnosis and the start of ART was higher in participants with perinatal HIV infection compared with participants with heterosexually acquired HIV infection overall [17 (interquartile range (IQR) 4–111) vs. 8 (IQR 2–38) weeks, respectively], and highest in perinatally infected participants aged 10–14 years [49 (IQR 9–267) weeks]. The cumulative proportion with TCVF 5 years after starting ART was 9.6% [95% confidence interval (CI) 7.0−12.3%] in participants with perinatally acquired infection and 4.7% (95% CI 3.9−5.5%) in participants with heterosexually acquired infection, and highest in perinatally infected participants aged 10–14 years when starting ART (27.7%; 95% CI 13.2−42.1%). Across all participants, significant predictors of TCVF were those with perinatal HIV aged 10–14 years, African origin, pre-ART AIDS, NNRTI-based initial regimens, higher pre-ART viral load and lower pre-ART CD4. Conclusions The results suggest a beneficial effect of starting ART before adolescence, and starting young people on boosted PIs, to maximize treatment response during this transitional stage of development." @default.
• W2521009540 created "2016-09-23" @default.
• W2521009540 creator A5004174170 @default.
• W2521009540 creator A5012384912 @default.
• W2521009540 creator A5021053412 @default.
• W2521009540 creator A5029770079 @default.
• W2521009540 creator A5030902925 @default.
• W2521009540 creator A5030943230 @default.
• W2521009540 creator A5033012471 @default.
• W2521009540 creator A5037870737 @default.
• W2521009540 creator A5039272561 @default.
• W2521009540 creator A5039985712 @default.
• W2521009540 creator A5046461817 @default.
• W2521009540 creator A5047386035 @default.
• W2521009540 creator A5047438814 @default.
• W2521009540 creator A5049035721 @default.
• W2521009540 creator A5049260734 @default.
• W2521009540 creator A5049440373 @default.
• W2521009540 creator A5049601897 @default.
• W2521009540 creator A5053492555 @default.
• W2521009540 creator A5056504094 @default.
• W2521009540 creator A5062744631 @default.
• W2521009540 creator A5068835724 @default.
• W2521009540 creator A5073553172 @default.
• W2521009540 creator A5074373099 @default.
• W2521009540 creator A5074980560 @default.
• W2521009540 creator A5075282656 @default.
• W2521009540 creator A5076099897 @default.
• W2521009540 creator A5079940746 @default.
• W2521009540 creator A5081460531 @default.
• W2521009540 creator A5081694461 @default.
• W2521009540 creator A5082570595 @default.
• W2521009540 creator A5085571849 @default.
• W2521009540 creator A5015788051 @default.
• W2521009540 date "2016-09-14" @default.
• W2521009540 modified "2023-10-18" @default.
• W2521009540 title "Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe" @default.
• W2521009540 cites W1517608807 @default.
• W2521009540 cites W1558056931 @default.
• W2521009540 cites W1597248718 @default.
• W2521009540 cites W1935628665 @default.
• W2521009540 cites W1991533907 @default.
• W2521009540 cites W2000416073 @default.
• W2521009540 cites W2011424438 @default.
• W2521009540 cites W2012392023 @default.
• W2521009540 cites W2031843016 @default.
• W2521009540 cites W2035095394 @default.
• W2521009540 cites W2038260752 @default.
• W2521009540 cites W2064388369 @default.
• W2521009540 cites W2069045954 @default.
• W2521009540 cites W2125756020 @default.
• W2521009540 cites W2141619032 @default.
• W2521009540 cites W2162030461 @default.
• W2521009540 cites W2168039974 @default.
• W2521009540 cites W2170528767 @default.
• W2521009540 cites W95542454 @default.
• W2521009540 doi "https://doi.org/10.1111/hiv.12411" @default.
• W2521009540 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5298034" @default.
• W2521009540 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27625109" @default.
• W2521009540 hasPublicationYear "2016" @default.
• W2521009540 type Work @default.
• W2521009540 sameAs 2521009540 @default.
• W2521009540 citedByCount "44" @default.
• W2521009540 countsByYear W25210095402017 @default.
• W2521009540 countsByYear W25210095402018 @default.
• W2521009540 countsByYear W25210095402019 @default.
• W2521009540 countsByYear W25210095402020 @default.
• W2521009540 countsByYear W25210095402021 @default.
• W2521009540 countsByYear W25210095402022 @default.
• W2521009540 countsByYear W25210095402023 @default.
• W2521009540 crossrefType "journal-article" @default.
• W2521009540 hasAuthorship W2521009540A5004174170 @default.
• W2521009540 hasAuthorship W2521009540A5012384912 @default.
• W2521009540 hasAuthorship W2521009540A5015788051 @default.
• W2521009540 hasAuthorship W2521009540A5021053412 @default.
• W2521009540 hasAuthorship W2521009540A5029770079 @default.
• W2521009540 hasAuthorship W2521009540A5030902925 @default.
• W2521009540 hasAuthorship W2521009540A5030943230 @default.
• W2521009540 hasAuthorship W2521009540A5033012471 @default.
• W2521009540 hasAuthorship W2521009540A5037870737 @default.
• W2521009540 hasAuthorship W2521009540A5039272561 @default.
• W2521009540 hasAuthorship W2521009540A5039985712 @default.
• W2521009540 hasAuthorship W2521009540A5046461817 @default.
• W2521009540 hasAuthorship W2521009540A5047386035 @default.
• W2521009540 hasAuthorship W2521009540A5047438814 @default.
• W2521009540 hasAuthorship W2521009540A5049035721 @default.
• W2521009540 hasAuthorship W2521009540A5049260734 @default.
• W2521009540 hasAuthorship W2521009540A5049440373 @default.
• W2521009540 hasAuthorship W2521009540A5049601897 @default.
• W2521009540 hasAuthorship W2521009540A5053492555 @default.
• W2521009540 hasAuthorship W2521009540A5056504094 @default.
• W2521009540 hasAuthorship W2521009540A5062744631 @default.
• W2521009540 hasAuthorship W2521009540A5068835724 @default.
• W2521009540 hasAuthorship W2521009540A5073553172 @default.
• W2521009540 hasAuthorship W2521009540A5074373099 @default.
• W2521009540 hasAuthorship W2521009540A5074980560 @default.
• W2521009540 hasAuthorship W2521009540A5075282656 @default.
• W2521009540 hasAuthorship W2521009540A5076099897 @default.

• next